Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment ; volume:16 ; number:2 ; day:3 ; month:5 ; year:2023 ; pages:108-112 ; date:6.2023
Magazine of European Medical Oncology ; 16, Heft 2 (3.5.2023), 108-112, 6.2023
- Creator
-
Mutz-Rabl, Christiane G.
Koelblinger, Peter
Koch, Lukas
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12254-023-00881-6
- URN
-
urn:nbn:de:101:1-2023091012584386053634
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mutz-Rabl, Christiane G.
- Koelblinger, Peter
- Koch, Lukas
- SpringerLink (Online service)
Other Objects (12)
Immunotherapy of malignant melanoma
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Beyond PD-1 Immunotherapy in Malignant Melanoma
Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
The age of enlightenment in melanoma immunotherapy
Advances in predictive biomarkers for melanoma immunotherapy
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Targeted Therapy and Immunotherapy for Melanoma in Japan
Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility
Extensive necrosis of visceral melanoma metastases after immunotherapy
Targeting regulatory T cells for immunotherapy in melanoma
GRADE-ing the Benefit/Risk Equation in Food Immunotherapy
Immunotherapy of malignant melanoma
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Beyond PD-1 Immunotherapy in Malignant Melanoma
Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
The age of enlightenment in melanoma immunotherapy
Advances in predictive biomarkers for melanoma immunotherapy
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Targeted Therapy and Immunotherapy for Melanoma in Japan
Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility
Extensive necrosis of visceral melanoma metastases after immunotherapy
Targeting regulatory T cells for immunotherapy in melanoma
GRADE-ing the Benefit/Risk Equation in Food Immunotherapy
Immunotherapy of malignant melanoma
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Beyond PD-1 Immunotherapy in Malignant Melanoma
Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
The age of enlightenment in melanoma immunotherapy
Advances in predictive biomarkers for melanoma immunotherapy
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Targeted Therapy and Immunotherapy for Melanoma in Japan
Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility
Extensive necrosis of visceral melanoma metastases after immunotherapy
Targeting regulatory T cells for immunotherapy in melanoma